Asset Details
Do you wish to reserve the book?
Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
Do you wish to request the book?
Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
2021
Overview
The characterization of circulating tumor cells (CTCs) holds promises for precision medicine because these cells are an important clinical indicator of treatment efficacy. We established the first and still only nine permanent colon CTC lines from peripheral blood samples of a patient with metastatic colon cancer collected at different time points during treatment and cancer progression. The study objectives were (
i
) to compare the gene expression profiles of these CTC lines, and (
ii
) to determine the main features acquired during treatment. The number of upregulated genes was higher in the CTC lines obtained after treatment, indicating that they acquired properties to escape treatment pressure. Among these upregulated genes, some are involved in the mTOR and PI3K/AKT signaling pathways. Moreover, cytidine deaminase expression was significantly increased in the CTC lines obtained after failure of the first- and second-line 5-fluorouracile-based treatments, suggesting that these CTCs can eliminate this specific drug and resist to therapy. Several enzymes involved in xenobiotic metabolism also were upregulated after treatment, suggesting the activation of detoxification mechanisms in response to chemotherapy. Finally, the significant higher expression of aldolase B in four of the six CTC lines obtained after treatment withdrawal and cancer progression indicated that these clones originated from liver metastases. In conclusion, these CTC lines generated at different time points during treatment of metastatic colon cancer in a single patient are characterized by the deregulation of different genes that promote (
i
) drug resistance, (
ii
) xenobiotic and energy metabolism, and (
iii
) stem cell properties and plasticity.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
1-Phosphatidylinositol 3-kinase
/ ALDOB
/ Biochemistry, Molecular Biology
/ Biomedical and Life Sciences
/ Biopsy
/ Cancer
/ CDA
/ Cloning
/ Colonic Neoplasms - genetics
/ Colonic Neoplasms - pathology
/ Computational Biology - methods
/ Drug Resistance, Neoplasm - drug effects
/ Enzymes
/ Genes
/ Genomics
/ Humans
/ Hépatology and Gastroenterology
/ Liver
/ Liver Neoplasms - metabolism
/ Neoplastic Cells, Circulating
/ Neoplastic Cells, Circulating - drug effects
/ Neoplastic Cells, Circulating - metabolism
/ Neoplastic Cells, Circulating - pathology
/ Oncology
/ Patients
/ Tumors
